Emerging role of rhomboid family proteins in mammalian biology and disease  by Bergbold, Nina & Lemberg, Marius K.
Biochimica et Biophysica Acta 1828 (2013) 2840–2848
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamemReview
Emerging role of rhomboid family proteins in mammalian biology
and disease☆
Nina Bergbold, Marius K. Lemberg ⁎
Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), DKFZ-ZMBH Allianz, Im Neuenheimer Feld 282, 69120 Heidelberg, GermanyAbbreviations: EGFR, epidermal growth factor recepto
L1, loop 1; LPS, lipopolysaccharide; RIP, regulated intram
☆ This article is part of a special issue entitled: Intram
⁎ Corresponding author. Tel.: +49 6221 545889.
E-mail address: m.lemberg@zmbh.uni-heidelberg.de
0005-2736/$ – see front matter © 2013 Elsevier B.V. Al
http://dx.doi.org/10.1016/j.bbamem.2013.03.025a b s t r a c ta r t i c l e i n f oArticle history:
Received 29 December 2012
Received in revised form 26 February 2013
Accepted 26 March 2013
Available online 3 April 2013
Keywords:
Regulated intramembrane proteolysis
Pseudoenzyme
Protein trafﬁcking
Epidermal growth factor receptor signaling
ADAM17
Endoplasmic reticulum-associated protein
degradationFrom proteases that cleave peptide bonds in the plane of the membrane, rhomboids have evolved into a
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Rhomboids were ﬁrst discovered in Drosophila melanogaster, where
they act as key regulators of epidermal growth factor receptor (EGFR)
signaling [1,2]. By a speciﬁc cut in the transmembrane (TM) anchor,
Drosophila rhomboid proteases trigger the activation and secretion of
three growth factors called Spitz, Gurken and Keren [3–5]. Moreover,
Drosophila Rhomboid-1 became the founding member of a universally
conserved class of intramembrane serine proteases that fulﬁll a wide
range of functions ranging from regulated intramembrane proteolysis
(RIP) to degradation (see related reviews in this issue [6–8]). Extensive
mutagenesis studies and biochemical assays revealed that rhomboid
proteases use a catalytic histidine–serine dyad between conserved
TM segments of their polytopic rhomboid core domain to cleave their
substrates (Fig. 1) [4,9–12]. Invariant additional features include a tryp-
tophan–arginine (WR) motif found in loop 1 (L1) and an Engelman
helix dimerization motif (GxxxG) in TM segment 6. Several crystal
structures of the bacterial rhomboid protease GlpG solved to atomic
resolution revealed that the membrane-integral active site is formed
by a six-TM helix bundle, which is clamped sidewise by an unusual
L1 structure that resides in the upper leaﬂet of the lipid bilayer (for recent
review see [13]). Although still no physiological substrate is known,
mechanistically the Escherichia coli rhomboid GlpG is the best-studiedC
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Fig. 1.Mammalian rhomboid family proteins share a membrane-integral core domain.
Topology models for human rhomboid proteases (RHBDLs), iRhoms and derlins with
the conserved six-pass TM domain core in blue. Structurally important features such
as the Engelman TM helix–helix dimerization motif (GxxxG) and the L1 structure
extending sidewise into the membrane (WR) are shown. Extra domains including
the IRHD are highlighted in red. Of note, RHBDL4 and PARL lack the seventh
C-terminal TM helix (highlighted in red) and have instead additional domain fusions
(not shown). For RHBDLs the protease active site motifs ‘GxSG’ and ‘H’ form a catalytic
dyad between TM helices 4 and 6, whereas iRhoms have a ‘GPxG’ sequence.rhomboid protease. In addition, the GlpG fold became the structural
reference for an emerging class of catalytically inactive homologues
(Fig. 1) [14–16]. These so-called rhomboid pseudoproteases, which
include derlins and iRhoms (for ‘inactive rhomboid’), bind proteins
within the eukaryotic secretory pathway and control their fate by
either regulating their trafﬁcking or degradation. Emerging functional
parallels between the rhomboid proteases and their catalytically
inactive cousins are that they share the way how they interact
with proteins in the plane of the membrane—either to trigger their
release by a proteolytic cut or to hand them over to different cellular
factors.
While by the help of powerful genetics the function of Drosophila
rhomboids has been resolved, still much less is clear about the
function of the mammalian homologues. Even more challenging is
the analysis of proteolytically inactive rhomboid homologues.
However, recent work, including the ﬁrst reports on knockout mice,
shows that mammalian rhomboid family proteins affect a number
of different processes such as intercellular signaling, wound healing
and protein degradation. In this reviewwe discuss the current knowl-
edge about the function of rhomboid family proteins in the mamma-
lian secretory pathway and ask whether they can be seen as new
targets for therapeutic intervention in human diseases. The emerging
function of the mitochondrial rhomboid protease PARL in organelle
homeostasis and Parkinson's disease is discussed in an accompanying
review in this issue [6].2. Conserved membrane-integral core domain deﬁnes the
rhomboid superfamily
Many genes have been annotated as rhomboid proteases based on
sequence similarity. This bioinformatic search also revealed several
close homologues lacking key catalytic residues, which are predicted
to be proteolytically inactive [15,17]. The Pfam protein family data-
base further includes the more distant homologues such as derlins
and the so far uncharacterized protein TMEM115, forming an extend-
ed superfamily of rhomboid-like proteins [18]. Currently 14 rhom-
boid family proteins are known, ﬁve rhomboid proteases and nine
catalytically inactive homologues (Table 1). Phylogeny suggests that
the so-called pseudoproteases have evolved by several independent
gene duplication events of proteolytic rhomboids, followed by diver-
siﬁcation and loss of activity (Fig. 2) (see recent review [19]). All
members of the rhomboid superfamily share signiﬁcant sequence
conservation within a core of six TM domains, suggesting that their
membrane-integral part shows structural similarities (Fig. 1). Consis-
tent with this, human Derlin-1 has six TM segments, and not four as
initially suggested, and structure homology modeling predicts that
it shares with E. coli GlpG the rhomboid fold [16]. Relationship
between distant family members and the bona ﬁde rhomboid prote-
ases best can be seen by the conservation of characteristic signatures
such as the L1 ‘WR’ motif or the ‘GxxxG’ helix dimerization motif in
TM segment 6 (Table 1). A recent thermodynamic analysis of GlpG
showed that the rhomboid-fold is primarily formed by four discrete
regions including the ‘WR’ and ‘GxxxG’motifs, which by both packag-
ing and hydrogen bonding stabilize the structure of the protease [20].
Although not all these ‘keystones’ are strictly conserved for all rhom-
boid pseudoproteases, the high sequence similarity suggests that the
entire rhomboid superfamily shares the same protein fold and struc-
tural ﬂexibility. In a striking variability, most rhomboid proteases
have evolved additional TM helices and different globular domains
that are fused to the N- and C-terminus or extended loop insertions
(Fig. 1) [15,17]. Assuming that rhomboids have evolved from a
common ancestor with the basic six-TM domain structure, this
makes the rhomboid superfamily to a rare case where topology has
evolved by attachment of a single nonhomologous TM segment [15],
instead of a more typical internal gene duplication event [21].
Table 1
Characteristics of mammalian rhomboid family proteins.
Family member Localization Structural signatures Activity Function
RHBDL1/veinlet-like 1 Golgi WR (L1) GxSG (TMD4)GxxxG (TMD6) Protease (predicted) ?
RHBDL2 Plasma membrane WR (L1)GxSG (TMD4)GxxxG (TMD6) Protease RIP, abundance control
RHBDL3/veinlet-like 4 Endosomes WR (L1)GxSG (TMD4)GxxxG (TMD6) Protease (predicted) ?
RHBDL4/RHBDD1 ER WQR (L1)GxSG (TMD4)GxxxG (TMD6) Protease, ubiquitin-binding, p97-recruitment ERAD
PARL Mitochondrial inner membrane GxSG (TMD5)GxxxG (TMD7) Protease RIP, abundance control
iRhoms (1, 2) ER—Golgi GPAG (TMD4)GxxxG (TMD6) Pseudoprotease Trafﬁcking control, ERAD?
Derlins (1, 2, 3) ER WR (L1)GxxxG (TMD6) Pseudoprotease ERAD
UBAC2 ER WR (L1)GxxxG (TMD6) Pseudoprotease, ubiquitin-binding (predicted) ERAD
RHBDD2 Golgi YR (L1)GxxxG (TMD6) Pseudoprotease, (predicted) ?
RHBDD3 ? HR (L1)GxxxG (TMD6) Pseudoprotease, ubiquitin-binding (predicted) ?
TMEM115 ? WT (L1)GxxxG (TMD6) Pseudoprotease, (predicted) ?
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The ﬁrst gene of a mammalian rhomboid protease was cloned in
1998 when Drosophila Rhomboid-1 still was seen as a mysterious
activator of growth factor secretion and awaited its discovery as
intramembrane protease [22]. In analogy to the ﬂy gene, this protein
of unknown function was named RHBDL1 (for ‘rhomboid-like protein
1’). RHBDL2, the second mammalian rhomboid, later was shown to
share the activity of Drosophila Rhomboid-1 to cleave Spitz, whereas
RHBDL1 did not show any activity [4]. Currently, ﬁve rhomboid prote-
ases are known in mammals that scatter across all major cellular
organelles and are predicted to have various different functions
(Table 1) [15]. Fluorescence microscopy suggests that ectopically
expressed RHBDL1, like Drosophila Rhomboid-1, is a Golgi enzyme,
whereas RHBDL2 is found at the plasma membrane and RHBDL3
show a punctuated pattern characteristic for endosomal structures [23].
RHBDL4 initially has been suggested to be a mitochondrial protein
(also referred to as RHBDD1) [24], whereas our more recent sub-
cellular fractionation and ﬂuorescence microscopy analysis overcame
this view revealing that RHBDL4 localizes to the endoplasmic reticulum
(ER) [25]. In contrast, PARL is a true mitochondrial rhomboid protease
that localizes to the inner mitochondrial membrane [26,27].
3.1. Substrate identiﬁcation: key for functional characterization of
rhomboid proteases in the late secretory pathway
Rhomboid proteases initially have been thought to cleave only
type I membrane proteins. Recently several exceptions from thisrhomboid family proteins with six-TM doma
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Fig. 2. Phylogeny of human rhomboid family proteins in the secretory pathway. Phylogen
pseudoproteases (black) based on the conserved regions (L1, TM domains 2, 4, and 6) as drule have been described, suggesting that the substrate spectrum of
rhomboid proteases is broader than initially anticipated [25,28–30].
For the plasma membrane-localized RHBDL2 several substrates have
been identiﬁed by candidate testing, whereas for the other rhomboid
proteases in the late secretory pathway no substrates are known yet
(see below and Table 2). Since it has been suggested that RHBDL2 re-
quires proteolytic cleavage within L1 to become activated [31], the
question arises whether rhomboids are synthesized as zymogens
and if therefore upon ectopic expression of RHBDL1 and -3 no activity
was recorded. A number of functional assays, however, suggest that
rhomboids are constitutively active enzymes and differences in the
substrate speciﬁcity may explain the apparent lack of activity of cer-
tain RHBDLs. As for classical soluble proteases, rhomboids need to
be tightly controlled in order to prevent damage to the membrane
[32]. Because of the biophysical properties of the lipid bilayer, sub-
strate recognition of rhomboid proteases follows different principles
than for soluble enzymes [33]. For rhomboid proteases, two different
models for substrate recognition have been suggested. In the ﬁrst
model, the conformational ﬂexibility of the substrate peptide back-
bone combined with immersion of the membrane in the vicinity of
the rhomboid active site is sufﬁcient to provide speciﬁcity [34,35].
For the well-characterized Drosophila substrate Spitz, a glycine–
alanine motif has been shown to serve as a helix break that allows
unfolding of the TM domain into the rhomboid active site [34]. The
second model suggests that rhomboid proteases primarily recognize
a speciﬁc sequence surrounding the cleavage site, and that TM
helix-destabilizing residues are a secondary feature required for
some substrates only [36,37]. Although a recent paper challengesins
RHBDL1 O75783
RHBDL3 Q495Y4
RHBDL2 Q9NX52
iRhom1 Q4TT59
iRhom2 Q96CC6
TMEM115 Q12893
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UBAC2 Q8NBM4
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Derlin-1 Q9BUN8
Derlin-2 Q9GZP9
Derlin-3 Q96Q80
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PARL Q9H300
etic relationship of rhomboid proteases (highlighted in red) and catalytically inactive
etermined previously [15]. Swissprot accession numbers are indicated.
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Fig. 3. Putative role of RHBDL2 in the release of bioactive molecules and remodeling of
cell–cell contact points. The plasma membrane-localized RHBDL2 cleaves the type I
membrane protein thrombomodulin. The function of RHBDL2 in wound healing may
be the release of soluble bioactive ectodomain (a), or the regulation of cell adhesion
by shedding of anchoring points (b).
Table 2
Substrates of mammalian rhomboid proteases.
Family member Substrates References
RHBDL1/veinlet-like 1 –
RHBDL2 Drosophila Spitz [3]
Drosophila Gurken [5]
Thrombomodulin [23,41]
Ephrin-B2 & -B3 [43]
ProEGF [52]
ErbB-1 [53]
RHBDL3/veinlet-like 4 –
RHBDL4/RHBDD1 BIK1 [24]
TSAP6 [30]
PreTCRα, TCRα, MPZ-L170R, opsin−degron,
polycystin-1 truncations
[25]
Drosophila Spitz [35]
PARL OPA1 [91]
Omi/HtrA2 [92]
PINK1 [93–96]
PGAM5 [97]
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sequence speciﬁcity. Substrate recognition probably is modulated by
additional features ranging from trafﬁcking signals to helical second-
ary structure elements, which prevents access to potential rhomboid
protease consensus sites.
3.1.1. RHBDL2 is important for wound healing
The ﬁrst known physiological substrate of a mammalian rhomboid
protease was the cell-surface protein thrombomodulin [23], which
serves as high-afﬁnity thrombin receptor to modulate blood coagula-
tion [38]. In addition thrombomodulin has various other functions in-
cluding the control of cell adhesion and migration in processes such
as wound healing [39]. Several proteases have been implicated in
thrombomodulin shedding and soluble forms were detected that
served as indicator for endothelial damage [40]. Database mining for
Spitz-type TM substrate features combined with candidate testing
showed that ectopically expressed RHBDL2 cleaves thrombomodulin
[23]. Mutagenesis and domain swap experiments, however, revealed
that the Spitz-type substrate motif was an ancillary feature and in-
stead the cytosolic thrombomodulin tail was essential and sufﬁcient
to drive RHBDL2-catalyzed cleavage [23]. Later work on the substrate
speciﬁcity showed that thrombomodulin ﬁt the cleavage site speciﬁc-
ity observed for bacterial rhomboids, supporting the hypothesis that
certain rhomboid proteases are controlled primarily by sequence spe-
ciﬁc substrate recognition [37]. Physiological relevance of RHBDL2-
catalyzed thrombomodulin shedding was recently provided by an in
vitro wound-healing assay [41]. This report of endogenous RHBDL2
activity in thrombomodulin processing demonstrated its crucial
role in remodeling of cell–cell contact points. Although the soluble
thrombomodulin ectodomain acts as a mitogen [42], and it efﬁciently
promotes wound healing, it is not clear whether RHBDL2 activity also
plays a direct role in remodeling of cell–cell contact points (Fig. 3)
[41]. Further work including studies in RHBDL2 knockout mice will
be required to resolve the underlying molecular events and the phys-
iological relevance of RHBDL2 activity in wound healing.
3.1.2. RHBDL2 cleaves the cell-adhesion and signaling molecule ephrin
Further work showed that ectopically expressed RHBDL2 cleaves
ephrin-B3 and to a lower extend ephrin-B2 [43]. This cleavage was
dependent on a Spitz-type TM helix break and is not affected by the
cytosolic substrate tail. Ephrins are a heterogeneous protein family
that by binding to cognate ephrin receptors modulate cell motility
and adhesion [44]. In addition to driving bidirectional signaling via ty-
rosine phosphorylation, receptor binding has been observed to trig-
ger proteolytic processing of various different ephrins [45–47].
Although the molecular details of these shedding events in most cir-
cumstances are not completely clear yet, ADAM-catalyzed cleavageof ephrin-A2 has been shown to control axonal repulsion by termi-
nating high-afﬁnity cell–cell contact points [45]. Whether RHBDL2-
catalyzed cleavage of ephrins-B2 and -3 similarly is involved in
remodeling of cell–cell contacts remains to be addressed.
3.1.3. Noncanonical activation of EGF by RHBDL2
Like the Drosophila growth factors, also mammalian EGFR ligands
are synthesized as membrane-tethered precursors and are only active
upon proteolytic release [48]. Despite being the trigger of EGFR sig-
naling in Drosophila, until recently, it was a commonly accepted
view that mammalian rhomboid proteases are not involved. Instead,
there is compelling evidence that ADAM proteases are key for the ac-
tivation of mammalian EGFR ligands [48–50]. For some EGFR ligands
such as proEGF, however, also other proteases such as kallikreins con-
tribute to proteolytic processing [51]. Recent work showed that in
several tumor cell lines endogenous RHBDL2 is able to cleave and ac-
tivate proEGF, whereas no other RHBDL showed activity on this sub-
strate [52]. The TM domain of proEGF has no Spitz-type helix-break,
corroborating that RHBDL2 can recruit its substrate by alternative
mechanisms. As had been observed for other rhomboid proteases,
proEGF is cut by RHBDL2 just outside the TM domain. Interestingly,
like for thrombomodulin, also the cleavage site of proEGF ﬁts the con-
sensus of bacterial rhomboid proteases [37,52]. Taken together with
the lack of any helix-breaking residue in the TM domain, this suggests
that for proEGF sequence speciﬁcity provides the main layer of con-
trol. Mutation of the rhomboid cleavage site or RHBDL2 knockdown
both had no effect on ADAM protease dependent EGF shedding, indi-
cating that the rhomboid- and metalloprotease-dependent pathways
act in parallel rather than serially [52]. Whether RHBDL2 plays a cru-
cial role in EGFR signaling in vivo and whether its inhibition offers a
new therapeutic intervention in cancer will be interesting questions
to be addressed in the future.
3.1.4. Does RHBDL2 affect receptor down-regulation?
Another link of RHBDL2 to modulation of EGFR signaling is provided
by the identiﬁcation of EGFR, also known as ErbB-1, as its fourth sub-
strate [53]. EGFR/ErbB-1 activity is modulated by several mechanisms in-
cluding its ubiquitin-mediated endocytosis, which ensures termination
cytosol
ER
Fig. 4. RHBDL4 promotes degradation of membrane proteins. ER-resident RHBDL4
cleaves unstable membrane proteins in an ubiquitin dependent manner (1). Cleavage
fragments are dislocated into the cytosol (2) dependent on the AAA+-type ATPase
p97 and are ﬁnally degraded by the cytosolic proteasome (3).
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activation mechanism may be provided by ligand-induced shedding of
ErbB-1. Although for the related receptor tyrosin kinase ErbB-4, ADAM
protease and γ-secretase catalyzed RIP have been reported by several
laboratories [55–57], just recently ectopically expressed RHBDL2
has been shown to cleave ErbB-1 [53]. Rhomboid-catalyzed ErbB-1
processing is stimulated by ligand-binding and ionomycin-induced
calcium signaling, suggesting that shedding is part of the physiological
receptor downregulation. Like for all other RHBDL2 substrates, upon
cleavage the ectodomain of ErbB-1 is released into the extracellular
space. Interestingly, following RHBDL2-catalyzed cleavage, the C-
terminal fragment remains predominantly in the membrane fraction
and only a minor portion was observed in the nucleus [53]. This is
strikingly different to γ-secretase catalyzed intramembrane cleavage
of ErbB-4, which leads to an efﬁcient release and nuclear accumulation
of a transcriptionally active intracellular domain [57]. Although
the RHBDL2-cleavage site in ErbB-1 has not been determined yet,
this difference suggests that shedding by RHBDL2 occurs in the
juxtamembrane region and leaves the TM anchor intact. Whether
RHBDL2 acts similarly to ADAM sheddase and γ-secretase to trigger
signaling to the nucleus or whether RHBDL2 only inactivates cell
surface receptors remains to be studied. From a mechanistic point of
view, RHBDL2-catalyzed cleavage of ErbB-1 is the intriguing ﬁrst report
of a ligand-dependent rhomboid substrate cleavage [53].
3.1.5. In search of RHBDL1 and RHBDL3 substrates
Although ectopic expression of RHBDL1 and RHBDL3 leads to par-
tial colocalization with RHBDL2 substrates [23], so far no signiﬁcant
proteolytic activity has been reported. Since both proteases show all
essential active site residues (see Table 1), we may envision that
they are active rhomboid proteases but show a different substrate
spectrum than RHBDL2 and Drosophila Rhomboid-1. Therefore,
more potent methods for substrate identiﬁcation are urgently needed
to decipher the function of RHBDL1 and RHBDL3. Expression proﬁling
suggests that RHBDL3 plays a role in pancreas development [58].
More recently, a microarray study in post mortem human brains re-
vealed a correlation between RHBDL3 gene expression and chrono-
logical aging, suggesting that this rhomboid activity is causally
related to the aging phenotype [59]. However, this remains specula-
tive until substrates of RHBDL3 are identiﬁed and its activity in
aging cells has been measured.
3.2. RHBDL4 promotes ER-associated degradation
Consistent with its distinct phylogenetic origin, RHBDL4 is sub-
stantially different from the three other rhomboid proteases in the
secretory pathway. By lacking the seventh TM domain, which is a
characteristic feature of eukaryotic rhomboid proteases, it possibly
resembles a close relative of an ancestral rhomboid common to all
kingdoms of life [15]. Another surprising ﬁnding was that RHBDL4 lo-
calizes to the ER [25], which is commonly assumed to be a protease
free zone. This makes sense, since the major function of the ER is pro-
tein folding [60], and not fully matured proteins have to be protected
from inappropriate proteolysis. Despite that, misfolded proteins have
to be efﬁciently removed from the ER, in order to avoid accumulation
of toxic aggregates. Consistent with its localization, RHBDL4 is part of
the ER-associated protein degradation (ERAD) machinery [25]. Al-
though the molecular details of ERAD have not been fully resolved
yet, work by a number of labs showed that aberrant proteins are usu-
ally dislocated from the ER into the cytosol as full-length proteins
where they become degraded by the ubiquitin proteasome system
[61]. However, RHBDL4-triggered degradation is different, leading to
clipping of ERAD substrates already in the ER membrane. Interesting-
ly, RHBDL4 can also cleave within luminal loops and TM regions of
polytopic membrane proteins (Table 2) [25,30]. ER localization
posed the question how RHBDL4 is regulated in the absence ofcontrolled substrate trafﬁcking. An unexpected twist to rhomboid
biology is that RHBDL4 is the ﬁrst intramembrane protease that spe-
ciﬁcally recognizes substrate ubiquitination by a cytosolic ubiquitin-
interacting motif (Fig. 4) [25]. This is functionally linked to the canon-
ical ERAD pathways since ubiquitination of RHBDL4 substrates is
dependent on E3 protein ligases such as gp78. Different to all previ-
ously characterized rhomboid proteases, RHBDL4-generated cleavage
products are not secreted [25]. Instead, luminal fragments are
retained in the ER, dislocated into the cytosol and ﬁnally degraded
by the proteasome. The nature of the protein-conducting channel
that mediates passage of ERAD substrates and their cleavage frag-
ments through the membrane is not known. However, we observed
that RHBDL4 recruits the AAA+-type ATPase p97 in order to use the
chemical energy of ATP to drive this reaction (Fig. 4). Ablation of
RHBDL4 activity leads to proteotoxic stress, indicating that clipping
of ERAD substrates plays a vital role in the control of ER protein ho-
meostasis [25]. The questions why RHBDL4 acts parallel to classical
ERAD dislocation pathways, and what the functional beneﬁt of
substrate clipping in the plane of the ER membrane is, remain to be
addressed. Of note, alternative RHBDL4 functions such as roles in
apoptosis regulation [24] and exosome biosynthesis [30] have been
suggested (see Table 2 for putative substrates).
4. Rhomboid pseudoproteases
A growing number of proteins are recognized as rhomboid family
members despite being predicted to be proteolytically inactive
[15–17]. Although the molecular understanding of these pseudo-
proteases is still at the beginning, the evolutionary relationship and
predicted structural parallels to the rhomboid fold indicate that they
share mechanistic features of how they interact with their protein
clients. The functional outcome and the fate of membrane-bound
proteins, however, are unrelated and catalytically inactive rhomboid
family members affect a wide range of different cellular pathways.
4.1. iRhoms
A striking sequence relationship exists between rhomboid prote-
ases and a tightly clustered group of homologues called iRhoms
Fig. 5. Role of Rhomboid pseudoproteases in the control of ER protein homeostasis.
Whereas iRhom binds its clients in the ER and guides them along the secretory path-
way to the Golgi (a), derlins are bona ﬁde ER proteins that in concert with other
ERAD factors determine their substrates for dislocation into the cytosol (b). By a mech-
anism that has not been determined yet, certain iRhom clients are retained in the ER
and funneled into the ERAD pathway (b).
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metazoan kingdom. However, since in the nematode Caenorhabditis
elegans both iRhom paralogues show an apparent intact catalytic
dyad [15], initially it was unclear whether they are proteases or not.
Strikingly, all iRhoms have a proline in the x-position of the apparent
‘GxSG’ catalytic motif, suggesting that the rhomboid fold is signiﬁ-
cantly altered and they have evolved a nonproteolytic function
(Fig. 1) [15]. Consistent with this hypothesis, the related proline
mutation kills the proteolytic activity of rhomboid proteases and all
iRhoms tested did not cleave any known rhomboid substrates [62].
In addition, iRhoms show two speciﬁc features that are not found in
any active rhomboid protease (Fig. 1). First, iRhoms show an extend-
ed cysteine-rich loop between TM domains 1 and 2, which because of
its high sequence conservation is called iRhom homology domain
(IRHD) [15]. Second, the conserved cytosolic N-terminal domain har-
bors several potential phosphorylation sites suggesting a regulatory
role [63]. The function of these iRhom-speciﬁc features is not
known, however, the high degree of sequence conservation taken to-
gether with putative gain-of-function mutations within the IRHD and
the N-terminus underscores their importance [64–66].
4.1.1. iRhom regulates activation of the sheddase ADAM17
Although iRhoms are not active proteases, their physiological func-
tion is linked to proteolytic ligand release. Two recent studies observed
that iRhom2 knockout mice injected with lipopolysaccharide (LPS), to
mimic a bacterial infection, showed reduced levels of secreted tumor
necrosis factor α (TNFα) [64,67]. As a consequence of the resulting im-
mune suppression, iRhom2-deﬁcient mice failed to control a bacterial
infection with Listeria monocytogenes [64]. This is because in macro-
phages, which are cells that secrete TNFα, iRhom2 acts as an essential
ER to Golgi trafﬁcking factor for the metalloprotease ADAM17 (also
known as TACE) [64,67,68]. In the Golgi, ADAM17 is activated like
many other proteases in the secretory pathway [69], which in turn is
an essential step for ADAM17-catalyzed release of TNFα [64,67,68].
Thereby iRhom2-controlled maturation deﬁnes a new layer of
ADAM17 regulation in macrophages. Interestingly, in a recent publica-
tion it has been shown that iRhom1, which in contrast to iRhom2 is
ubiquitously expressed, is responsible for ADAM17 maturation in
other cells than macrophages [70]. Consistent with a role in the im-
mune response, two main activators of inﬂammatory arthritis were
shown to stimulate iRhom2/ADAM17-dependent cleavage of TNFα.
Since iRhom2 expression is restricted to immune cells, its inactivation
will not inﬂuence ADAM17 functions in other cell-types, which
makes iRhom2 a potential drug target for inﬂammatory diseases [70].
Related to these ﬁndings, a recent report showed that iRhom2 is
expressed and transcriptionally upregulated in hepatocytes exposed
to LPS [63]. Here iRhom2 participates in ADAM17-catalyzed down-
regulation of the TNF receptor, which protects hepatocytes from
TNFα-induced apoptosis. Taken together with the ﬂurry of reports
that iRhom2 activates TNFα activity, this revealed ADAM17 trafﬁcking
as an important regulator, and if drugable, iRhom2 as a selective and
potential target for the treatment of inﬂammatory diseases.
4.1.2. iRhom in the abundance control of EGFR ligands
Another function of iRhoms has been observed in Drosophila,
where it inhibits EGFR signaling in the nervous system [62]. Different
to an initial hypothesis that the iRhom pseudoprotease directly blocks
active rhomboid proteases [17], it reduces the level of growth factor
substrates by triggering their degradation (Fig. 5) [62]. Consistent
with a link of iRhom to the ERAD pathway, Drosophila iRhom geneti-
cally interacts with the E3 ubiquitin ligase Hrd1 and the ERAD
substrate receptor EDEM [62]. In the same study, also mammalian
iRhoms have been shown to trigger ERAD of EGFR ligands [62]. The
emerging picture is that secretion of EGFR ligands is a highly dynamic
and regulated process and that iRhoms act as negative regulators of
EGFR ligand trafﬁcking. This suggests that iRhoms have bivalentfunctions; either promoting trafﬁcking to the Golgi, or blocking ER ex-
port of the ligand, which leads to its turnover by the ERAD pathway
(Fig. 5) [62,64,67]. Currently it is not clear how iRhom makes the
decision whether its clients are exported or degraded. We may spec-
ulate that iRhom regulates the ER export rate, the canonical ER quality
control and client properties such as N-linked glycans determine the
extent to which the client is degraded [71].
4.1.3. iRhoms implicated in cancer
With a potential to affect the cellular activity of two main players
of the EGFR pathway, the ADAM17 sheddase and EGFR ligands, iRhom
emerges as a master regulator, suggesting that its expression level has
to be tightly controlled [62,64,67]. Consistent with such an important
role in EGFR signaling, it has been shown that misregulated iRhom
levels affect cancer development and tumor growth [66,72,73].
Although the underlying mechanisms have not been resolved yet,
high throughput sequencing revealed that missense mutations in
the iRhom2 gene cause tylosis with esophageal cancer and other
iRhom2 mutations may play a role in ovarian cancer [65,66,74]. The
hyperproliferative phenotype observed in the esophageal cancer
cells implies that altered iRhom2 levels lead to sustained EGFR signal-
ing [66]. A link of iRhoms to EGFR signaling in humans is further sup-
ported by the fact that iRhom1 physically interacts with transforming
growth factor α [75]. Moreover, siRNA-mediated iRhom1 knockdown
in tissue culture cells has been described to diminish EGFR
transactivation, which is the crosstalk between G-protein coupled re-
ceptors and the EGFR [73]. The physiological relevance of this link to
EGFR transactivation, however, remains to be investigated. In conclu-
sion, both mammalian iRhom paralogues have been linked by several
lines of evidence to key signaling pathways, suggesting that tuning
their activity may be a promising new therapeutic strategy for disease
intervention.
4.2. Derlins
More distant rhomboid family proteins are derlins (Fig. 2) [12,16].
The ﬁrst example Der1 (for ‘degradation in the ER’) was identiﬁed by
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Later, it was shown to interact with the E3 ubiquitin ligase Hrd1 and
the AAA+-type ATPase Cdc48 (known as p97 in mammals) in order
to extract aberrant luminal and membrane-anchored proteins [77,78].
Likewise, human derlins were shown to be central ERAD factors.
Derlin-1 was identiﬁed by two independent mass spectrometry-
based approaches probing the environment of factors involved
in ERAD [79,80]. Subsequently, Derlin-1 was shown to act in a
multiprotein network that mediates ERAD of a heterogeneous set of
proteins including disease-associated mutants of the polytopic mem-
brane protein CFTR (for ‘Cystic ﬁbrosis transmembrane conductance
regulator’) [78,81–83]. Likewise, the two other human paralogues,
namely Derlin-2 and -3, are involved in ERAD [82,84]. The molecular
function of derlins is still unclear and it is not known what determines
the speciﬁcity between derlin paralogues. Although they have been
suggested to form a protein-conduction pore for ‘retrotranslocation’
of ERAD substrates, a recent revision of their TM topology and a struc-
ture homology model indicate that they have a rhomboid fold instead
[16]. Intriguingly, the characteristic ‘WR’ and ‘GxxxG’ motifs (see
Fig. 1), which are both crucial for rhomboid protease activity and
stability, are also key for Derlin-1-mediated protein dislocation [16].
Assuming that the rhomboid superfamily share the way they interact
with substrates and clients, derlins may serve as receptors for ERAD
substrates that use the membrane-perturbing action of the rhomboid
domain to facilitate dislocation into the cytosol (Fig. 5) [61,71].
4.3. New emerging catalytically inactive rhomboid family proteins
Based on sequence comparison, several so far functionally
uncharacterized proteins are predicted to belong to the rhomboid su-
perfamily (Fig. 2). Since these more distant rhomboid family proteins
show clear differences to rhomboid protease signature (Table 1), it
remains to be investigated whether they are all structurally related.
The limited overall sequence conservation suggests that these putative
rhomboid pseudoproteases fulﬁll different functions. UBAC2 (for
‘ubiquitin-associated domain-containing protein 2’) has been shown
by a proteomics and functional genomics study to serve as an ERAD
factor [82]. This is supported by the fact that UBAC2 is upregulated
upon ER stress, suggesting a vital role in the control of ER protein ho-
meostasis. More recently, UBAC2 has been shown to restrict trafﬁcking
of the adipose triglyceride lipase regulator UBXD8 from the ER to lipid
droplets, indicating a link to the control of cellular lipid storage [85].
How UBAC2 exactly interplays with the ERAD pathway and regulates
lipid droplet turnover, however, remains to be investigated. The
function of three other highly conserved rhomboid pseudoproteases,
namely RHBDD2, RHBDD3 and TMEM115 (Table 1), is not known.
For Golgi-resident RHBDD2, a missense mutation in the RHBDD2 gene
hints to a role in the onset of retinitis pigmentosa [86]. Furthermore, el-
evated expression levels in breast and colorectal cancer indicate a role
in tumorigenesis [87–89]. Not only because of their clinical relevance, it
will be interesting to reveal the function and the molecular mechanism
of these just emerging classes of rhomboid family proteins.
5. Concluding remarks
After the discovery that rhomboids are intramembrane proteases,
progress on the mammalian homologues was initially slow. Although
they can be inhibited with a broad-spectrum serine protease inhibitor
dichloroisocoumarin [4,11,12], the short half live and toxicity limit the
applicability of this compound, still making the analysis of endogenous
rhomboid activity challenging. A recent in vitro drug screen with bacte-
rial rhomboid proteases identiﬁed β-lactams as potential lead com-
pound that also inhibit RHBDL2 [90], raising hopes that in the future
more potent and selective rhomboid protease inhibitors may ﬁnd appli-
cation as therapeutic drugs [33]. Moreover, several new substrates for
mammalian rhomboid proteases have been identiﬁed and ﬁrst reportshave started to illuminate the function of catalytically inactive homo-
logues. Although still several putative rhomboid pseudoproteases have
not been functionally characterized, it already becomes clear that the
rhomboid superfamily affects the fate of membrane proteins inmany bi-
ological andmedical important contexts. Inevitably, the recent work has
also posed new questions. Among them, a fundamental unsolved prob-
lem is how rhomboid proteases and their catalytically inactive cousins
speciﬁcally interact with substrates and clients. Moreover, we still strug-
gle in ﬁnding endogenous substrates and clients. In order to allow phys-
iological conclusions, more efﬁcient and unbiased methods for substrate
identiﬁcation are urgently needed. Together with a detailed functional
characterization of the rhomboid superfamily, this will likely help to re-
veal new mechanisms important for human biology and disease. Since
rhomboid family proteins are key players of various important biological
pathways, which when disturbed can lead to inﬂammatory diseases and
cancer, likely it will be just a matter of time until the ﬁrst drugs are
targeting this class of proteins.
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